Adipose tissue macrophage (ATM)-driven inflammation plays a key role in insulin resistance; however, factors activating ATMs are poorly understood. Using a proteomics approach, we show that markers of classical activation are absent on ATMs from obese humans but are readily detectable on airway macrophages of patients with cystic fibrosis, a disease associated with chronic bacterial infection. Moreover, treating macrophages with glucose, insulin, and palmitate-conditions characteristic of the metabolic syndrome-produces a ''metabolically activated'' phenotype distinct from classical activation. Markers of metabolic activation are expressed by proinflammatory ATMs in obese humans/mice and are positively correlated with adiposity. Metabolic activation is driven by independent proinflammatory and anti-inflammatory pathways, which regulate balance between cytokine production and lipid metabolism. We identify PPARg and p62/SQSTM1 as two key proteins that promote lipid metabolism and limit inflammation in metabolically activated macrophages. Collectively, our data provide important mechanistic insights into pathways that drive the metabolic-disease-specific phenotype of macrophages.
INTRODUCTION
Macrophages accumulate in adipose tissue of obese mice and humans (Weisberg et al., 2003; Xu et al., 2003) and are key contributors to inflammation and obesity-induced insulin resistance (Chawla et al., 2011; Lumeng and Saltiel, 2011; Olefsky and Glass, 2010; Wellen and Hotamisligil, 2005) . The evidence implicating adipose tissue macrophage (ATM) inflammation in potentiating insulin resistance is substantial. Indeed, ablation of proinflammatory (CD11c + ) ATMs using a diphtheria toxin system led to rapid improvements in insulin sensitivity and glucose tolerance, associated with marked decreases in local and systemic inflammation in obese mice (Patsouris et al., 2008) . Moreover, targeting pathways that mediate inflammation in the macrophage revealed significant roles for TLR4, JNK, and IKKb in potentiating ATM inflammation and insulin resistance in mice (Arkan et al., 2005; Han et al., 2013; Saberi et al., 2009) . Anti-inflammatory effects may also help explain the insulin-sensitizing action of thiazolidinediones (TZDs). Indeed, myeloid-specific deletion of PPARg, the molecular target of TZDs, exacerbated macrophage inflammation and insulin resistance (Odegaard et al., 2007) . Macrophages are heterogeneous, and based on patterns of gene expression and function, they have been classified as classically (M1) or alternatively (M2) activated (Gordon and Taylor, 2005) . The M1 phenotype is promoted by Th1 mediators such as LPS and IFNg and is characterized by the overproduction of proinflammatory cytokines. In contrast, Th2 mediators (e.g., IL-4) drive the M2 phenotype, which activates expression of immunosuppressive factors and peroxisome proliferator-activated receptor gamma (PPARg) that promote tissue remodeling and helps resolve inflammation (Odegaard et al., 2007) . It has been proposed that during weight gain macrophages undergo a ''phenotypic switch'' from an anti-inflammatory M2 phenotype to a proinflammatory M1 state, a conversion that has been linked to the emergence of systemic insulin resistance (Lumeng et al., 2007) .
Although it is clear that ATM activation is involved in regulating insulin sensitivity, the mechanisms that underlie transition to the proinflammatory ATM phenotype and corresponding signature of cell surface markers are poorly understood. For example, CD11c, the most commonly used marker of proinflammatory ATMs in mice and humans, is suppressed by the classical activation paradigm of LPS stimulation (Becker et al., 2012) . More recently, Ferrante and colleagues provided evidence that ATMs in obese mice exhibit increased lipid metabolism and further suggested that increases in ATM number, rather than ATM activation, may be responsible for the low-grade inflammation observed in obesity (Xu et al., 2013) . In addition, several studies have described a ''mixed'' M1/M2 phenotype for ATMs in obese mice and humans, suggesting that ATMs adopt more complex states in vivo (Sica and Mantovani, 2012; Zeyda et al., 2007) . However, the etiologies of such mixed M1/M2 phenotypes are incompletely understood.
Here we combine proteomic, gene expression, and flow cytometric analyses of human and murine macrophages; studies of cells from obese, nonobese, and cystic fibrosis (CF) patients; and murine knockout studies to characterize proinflammatory ATMs and to identify the molecular mechanisms that produce them. Our findings demonstrate that treating macrophages with mixtures of glucose, insulin, and palmitate (i.e., ''metabolic activation'') produces a complex macrophage phenotype that is mechanistically distinct from classical activation, suggesting that metabolic-disease-specific pathways drive macrophage inflammation via mechanisms that are different from those operative during infection.
RESULTS

Plasma Membrane Proteomics Identifies Markers of M1 Macrophages
The lack of specific markers for human macrophage subsets is a major hurdle to understanding ATM inflammation in obese and diabetic patients (Geissmann et al., 2010) . We therefore used a plasma membrane (PM) proteomics approach to define protein expression patterns diagnostic of proinflammatory human macrophages. Initial studies focused on a widely used in vitro system that included classically activated (M1, proinflammatory), alternatively activated (M2, anti-inflammatory), and unstimulated (M0) macrophages generated from human peripheral blood monocytes (Mn) in the presence of M-CSF (MM0, MM1, and MM2) or GM-CSF (GM0, GM1, and GM2) ( Figure 1A ). Classical and alternative activation were confirmed by measuring expression of genes associated with the M1 and M2 phenotypes (Figure S1 available online) .
PM-associated proteins were biotinylated, affinity-isolated, and analyzed by liquid chromatography-electrospray ionization-tandem mass spectrometry. This approach identified 349 proteins with high confidence (Table S1 ). Gene ontology analysis of those proteins validated our analytical strategy by revealing strong enrichments in functional annotations consistent with the PM compartment of macrophages ( Figure S1 ).
Protein levels were quantified by spectral counting (Liu et al., 2004) , a measure of relative protein abundance, which were closely correlated with flow cytometry data ( Figure S1 ). Markers of classically activated macrophages were selected by identifying proteins consistently upregulated (or downregulated) by both the t test and G test (Becker et al., 2010) in M1 cells relative to M2 and M0 cells. We identified 52 significantly regulated PM proteins in M1 macrophages differentiated by M-CSF or GM-CSF treatment ( Figure 1B ; Table S1 ). We further required that such markers were reproduced in macrophages differentiated in the presence of M-CSF and GM-CSF, as we thought this would increase their utility as markers in diverse environments in vivo. Based on these stringent criteria, we identified 13 membrane proteins as putative cell surface markers of M1 macrophages (Figures 1B and 1C ; Table S1 ).
We previously used a similar PM proteomics approach to define cell surface markers of M1 macrophages in mice (Becker et al., 2012) . Interestingly, only six of the M1 markers identified in human macrophages overlapped with those found in classically activated bone-marrow-derived murine macrophages (BMDMs). To promote continuity between human and mouse studies, our subsequent analyses focused on three such conserved markers (CD274, CD38, and CD319). Flow cytometric measurements validated the ability of CD274, CD38, and CD319 to reliably identify classically activated macrophages ex vivo using both human and murine macrophages ( Figures 1D and S1 ). Importantly, the induction of CD38 and CD319 on the cell surface of M1 cells was not attenuated by simultaneously exposing macrophages to M1 and M2 stimuli ( Figure 1E ), suggesting that these markers can report exposure to classical stimuli even in the context of a ''mixed'' macrophage phenotype, which is likely to be present in more complex conditions in vivo (Mosser and Edwards, 2008) .
To validate the ability of these markers to identify macrophages inflamed by bacterial stimuli in vivo, we tested the expression of CD38, CD319, and CD274 on airway macrophages from infected patients with CF, a disease characterized by heightened inflammatory responses in the airways due to chronic respiratory tract infection with pathogenic bacteria like Pseudomonas aeruginosa (Rowe et al., 2005) . Flow cytometric analysis detected strong expression levels for all three markers in all CF patients examined ( Figures 1F and S2) . Thus, our proteomics approach successfully identified macrophage markers expressed in an in vivo inflammatory condition caused by chronic bacterial infection.
ATMs from Obese Humans and Mice Do Not Express M1 Markers During obesity, macrophages have been proposed to undergo a ''phenotypic switch'' from an anti-inflammatory M2 phenotype to a proinflammatory M1 state (Lumeng et al., 2007) . To determine if the M1 markers discovered by proteomics and validated in patients with CF could identify proinflammatory ATMs, we studied macrophages from omental and subcutaneous adipose tissue obtained from obese (BMI > 30 kg/m 2 ) subjects undergoing bariatric surgery. For comparative purposes, we also investigated ATMs in subcutaneous adipose tissue obtained from nonobese (BMI < 30 kg/m 2 ) subjects undergoing abdominoplasty.
Although proinflammatory cytokine expression was elevated in both omental and subcutaneous adipose tissue from obese subjects (Figure 2A ), cell surface markers for M1 activation (CD38, CD274, and CD319) were either not present or only very weakly expressed by ATMs in either of the adipose tissue depots examined ( Figures 2B, 2C , and S3).
We also tested the ability of M1 markers to identify proinflammatory ATMs in mice. To this end, we used a mouse model for diet-induced obesity and insulin resistance (DIO), where male C57BL/6 mice were placed on low-fat or high-fat diets for 16 weeks. Analysis of ATMs from lean and obese mice recapitulated the findings obtained in human subjects. Thus, ATMs from obese mice were inflamed relative to their lean counterparts (Figure 2D ) but did not overexpress CD319, CD274, or CD40 (Figure 2E) , a previously characterized M1 marker in mice (Becker et. al., 2012) . Importantly, treating ATMs (purified from obese mice) with LPS/IFNg in vitro induced expression of CD319, CD274, and CD40, suggesting that ATMs are capable of adopting an M1 phenotype given the appropriate environment ( Figure 2F ). Collectively, these findings suggest that distinct surface markers report macrophage inflammation in a setting of bacterial infection and metabolic dysfunction.
''Metabolically'' and Classically Activated Macrophages Express Distinct Cell Surface Proteins The lack of M1 cell surface marker expression by proinflammatory ATMs in obese humans and mice suggested that distinct pathways might promote macrophage inflammation in the context of obesity, a hypothesis that has been proposed by Hotamisligil and colleagues (Calay and Hotamisligil, 2013; Hotamisligil and Erbay, 2008) . In the context of metabolic disease, macrophage inflammation may be regulated by molecules such as glucose, insulin, and palmitate, which are elevated in patients with metabolic disease (Despré s and Lemieux, 2006) . Thus, we hypothesized that exposure to high levels of glucose, insulin, and palmitate (''metabolic activation''; MMe) may produce a unique proinflammatory macrophage phenotype.
Classical and metabolic activation ( Figure 3A ) both induced proinflammatory cytokine expression ( Figure 3B ). However, MMe macrophages failed to express cell surface markers diagnostic of classically activated macrophages including CD38, CD319, and CD274 ( Figure 3C ), a finding that resembled our findings for proinflammatory ATMs isolated from obese humans and mice (Figures 2B and 2C) . To identify diagnostic cell surface markers of metabolic activation, we performed membrane proteomics of MM0, MM1, and MMe macrophages. Proteomics Table S1. analysis of metabolically and classically activated macrophages revealed remarkably distinct cell surface protein expression patterns (<5% overlap) ( Figure 3D ; Table S2 ). For example, cell surface proteins specifically overexpressed by MMe macrophages included ABCA1, CD36, and PLIN2 ( Figure 3E )-proteins involved in lipid metabolism that have been associated with M2 macrophages. However, the M2 markers CD163, CD206, TFRC, and TGFBI (Becker et al., 2012; Martinez et al., 2006) were suppressed or not induced in MMe macrophages (Figure 3F) , indicating that metabolic and alternative activation programs are distinct. In addition, proteomics analysis confirmed that MMe macrophages did not express markers of classical activation (Table S2 ).
Adipose Tissue Media Promotes ''Metabolic Activation'' of Macrophages
We considered the possibility that experimental exposure to mixtures of glucose, insulin, and palmitate may inadequately model in vivo ATM conditioning. To explore this, we treated human monocyte-derived macrophages with media conditioned by visceral adipose tissue from obese humans or mice and found that IL1b, TNFa, ABCA1, and CD36 expression were all induced (Figures 4A and 4B) . In sharp contrast, treatment with sputum from a CF patient enhanced IL1b and TNFa expression, and surface levels of CD274 and CD38, but failed to induce CD36 and PLIN2 in human macrophages (Figure 4A) . Thus, treating naive macrophages with disease-specific biological fluids (adipose media versus CF sputum) reproduces the distinct surface marker expression observed in airway macrophages and ATMs in vivo (Figures 2 and 4) .
Because adipocytes undergo lipolysis during culture and preferentially release palmitate into the medium, we hypothesized that palmitate was the major driver of metabolic activation. To test this hypothesis, we compared MMe macrophages with MM0 macrophages treated with glucose, insulin, or palmitate in isolation. Treatment with palmitate was sufficient to drive PLIN2 and IL1b expression, suggesting that it may be the main driver of metabolic activation ( Figure S4 ). We further confirmed that palmitate levels at the lower limit in type 2 diabetic patients (0.1 mM) (Reaven et al., 1988) could stimulate the MMe phenotype as well ( Figure S4 ).
ATMs of Obese Humans and Mice Display Evidence of ''Metabolic Activation''
We investigated if markers of metabolic activation were present on ATMs in vivo by quantifying ATM cell surface ABCA1 and CD36 levels in omental and subcutaneous adipose tissue from
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Metabolic-Disease-Specific Macrophage Inflammation obese subjects undergoing bariatric surgery. As before, subcutaneous adipose tissue obtained from nonobese (BMI < 30 kg/m 2 ) subjects undergoing abdominoplasty were used for comparative purposes. Cell surface CD36 and ABCA1 levels were elevated on ATMs from omental and subcutaneous adipose tissue in obese relative to nonobese subjects and relative to airway macrophages of CF patients ( Figure 4C and S3). Moreover, linear regression analysis revealed strong relationships between BMI and ATM CD36 levels (R 2 = 0.73, p = 0.0001, n = 14) or ABCA1 levels (R 2 = 0.40, p = 0.02, n = 14) in subcutaneous adipose tissue ( Figures 4D and 4E ), suggesting that macrophage metabolic activation correlates with adiposity. In sharp contrast, such relationships were absent for markers of M1 macrophages assessed in the same patients (CD38, CD319, and CD274; Figures 4D and 4E) . Analysis of ATMs from obese mice produced similar findings. Indeed, we observed increases in the expression of proinflammatory cytokines (Tnfa and Il1b) and MMe markers (Plin2 and Abca1) in ATMs isolated from obese mice ( Figure 4F ). Moreover, ATMs isolated from obese mice overexpressed seven of nine additional MMe markers identified in our proteomics analysis of human MMe macrophages ( Figure 4G ). Collectively, these findings are consistent with the notion that palmitate released from adipocytes promotes macrophage metabolic activation in vivo.
Proinflammatory Signaling Does Not Drive MMe Surface Marker Expression
The fact that M1 and MMe macrophages differed markedly in surface marker expression was surprising given that palmitate is thought to mimic LPS action by binding to TLRs (Himes and Smith, 2010; Shi et al., 2006) . This finding led us to hypothesize that different signaling pathways mediate the M1 and MMe phenotypes. To begin to test this hypothesis, we used bioinformatics Table S2. to identify specific cell signaling pathways linked to cell surface proteins expressed by MM1 (but not MMe) macrophages.
LPS binding to TLR4 stimulates proinflammatory cytokine production through the NFkB pathway and induces the type I interferon response via IRF7 (Beutler, 2004) . Consistent with this idea, bioinformatics analysis suggested that cell surface proteins selectively induced by MM1 macrophages were associated with the type I interferon response (p = 10 À30 ; Figure 5A ). To confirm the role of the type I interferon pathway in regulating M1 surface markers, we performed two experiments that engaged the NFkB pathway without a type I interferon response. First, we compared CD38, CD274, and CD319 expression in MM1 cells made from wild-type and type I interferon pathway-deficient (Ifnar À/À ) mice (Mü ller et al., 1994) . Ablation of Ifnar1 significantly lowered cell surface CD38, CD274, and CD319 expression in M1 macrophages ( Figure 5B ). Second, we stimulated human macrophages with the TLR2 agonist Pam2CSK4. Pam2CSK4 induced IL1b, TNFa, and IL6 expression to levels similar to MM1 macrophages ( Figure 5C ) but did not elicit the type I interferon response (Toshchakov et al., 2002) (Figure 5D ) or CD38, CD274, and CD319 expression ( Figure 5E ). In addition, Pam2CSK4 treatment did not elevate ABCA1, CD36, and PLIN2, suggesting that this agonist does not stimulate metabolic activation ( Figure 5F ).
Given that the type I interferon pathway controls CD38, CD274, and CD319 expression in M1 macrophages, and that MMe cells express different cell surface proteins, we postulated that that the type I interferon response would not be activated in these cells. As expected, neither human nor murine MMe macrophages exhibited IRF7 gene expression and IKKε phosphorylation ( Figures 5G, 5H , and S5), two key drivers of the type I interferon response (Honda et al., 2005) . Proinflammatory ATMs from obese mice also did not exhibit elevated IKKε 
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Metabolic-Disease-Specific Macrophage Inflammation phosphorylation or Irf7 gene expression relative to lean mice ( Figures 5I and 5J ). Since MMe macrophages fail to engage the type I interferon response, and activation of this pathway is a key feature of TLR4 activation, we investigated whether surface markers of MMe macrophages were dependent upon the presence of TLRs. Ablation of Tlr2 or Tlr4, which mediate the proinflammatory effects of palmitate on macrophages (Himes and Smith, 2010; Shi et al., 2006) , attenuated Il1b expression but did not alter Plin2 expression in MMe macrophages ( Figure 6A) . Collectively, these studies demonstrate that, unlike MM1 macrophages, cell surface markers of MMe macrophages are independent of the type I interferon pathway and TLR activation.
p62 and PPARg Promote MMe Surface Marker Expression
What molecular mechanisms drive cell surface marker expression in MMe macrophages? We used two approaches to exploit our proteomics data to identify signaling pathways controlling cell surface marker expression in MMe macrophages.
First, we used bioinformatics analysis and found that surface proteins selectively induced in MMe macrophages were involved in lipid metabolism and regulated by PPARg ( Figure 6B ; p = 10 À7 ). Consistent with the informatics data, chromatin immunoprecipitation (ChIP) studies demonstrated increased binding of PPARg to the promoters of PLIN2, ABCA1, and CD36 in human and murine MMe macrophages ( Figures 6C and S6) , and PPARg 
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Metabolic-Disease-Specific Macrophage Inflammation promoter binding correlated with histone H3K4 trimethylation (H3K4m3), an epigenetic mark for open chromatin ( Figure 6C ). Furthermore, a PPARg antagonist (T0070907; 1 mM) reduced ABCA1, PLIN2, and CD36 expression in MMe macrophages ( Figure S6) . Second, we searched the membrane proteome for proteins with well-established roles in cell signaling that were selectively induced in MMe macrophages. This analysis identified a strong and selective induction of sequestome-1 (p62) ( Figure 6D ). Moreover, p62 was significantly elevated in ATMs from obese relative to lean mice ( Figure 6D ). p62 is a scaffolding protein that regulates a variety of cell signaling cascades (Komatsu et al., 2007) . Previous studies suggest that p62 regulates adipocyte lipid metabolism and adiposity in mice (Mü ller et al., 2013; Rodriguez et al., 2006) . To determine if p62 regulates the MMe phenotype, we compared macrophages from wild-type and p62-deficient (p62 À/À ) mice and found Plin2, Abca1, and Cd36 expression was reduced in p62 À/À cells ( Figure 6E ). Thus, p62 and PPARg regulate expression of CD36, ABCA1, and PLIN2 in MMe macrophages.
p62 and PPARg Limit Inflammation during ''Metabolic Activation''
The induction of PPARg in proinflammatory MMe macrophages seemed surprising given that saturated FFAs are poor PPARg ligands (Wahli and Michalik, 2012) and that PPARg exerts antiinflammatory effects (Odegaard et al., 2007) . We examined the effect of PPARg on the inflammatory phenotype of MMe macrophages by treating cells with the PPARg antagonist T0070907. Consistent with an anti-inflammatory role of PPARg (Odegaard et al., 2007) , blocking PPARg with T0070907 increased expression of IL1b in MMe cells ( Figure S6 ). The p62 induction identified in MMe macrophages ( Figure 4D ) also had an anti-inflammatory effect, as p62 À/À macrophages markedly overproduced Tnfa and Il1b in response to metabolic, but not classical, activation ( Figure 6E ). These data indicate that p62 and PPARg attenuate proinflammatory cytokine production during metabolic activation, which may in part explain why the sterile inflammation associated with metabolic disease is often of lower intensity than that induced by bacterial infection. Cell Metabolism
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Palmitate Uptake Induces P62 Accumulation by Inhibiting Autophagy What mechanism induces p62 during metabolic activation? Whereas p62 is normally degraded by the autophagolysosome, it accumulates under conditions of failed autophagy (Komatsu et al., 2007) . Consistent with a blockade in autophagy in MMe macrophages, p62 protein accumulated in a time-dependent fashion ( Figure 6F) , and its accumulation could not be explained by increased transcription ( Figure 6G ). Similarly, LC3-II protein, another marker of failed autophagy (Shpilka et al., 2011) , also accumulated in MMe macrophages ( Figure 6F ). Moreover, treatment with chloroquine (an inhibitor of autophagy) induced LC3-II accumulation in MM0 macrophages but not in MMe macrophages ( Figure S7 ). How could metabolic activation inhibit autophagy? One possibility is that this inhibition of autophagy is linked to the proinflammatory state. Arguing against this possibility, MM1 macrophages did not accumulate p62 ( Figure 6D ), and inactivation of Tlr2 or Tlr4 in MMe macrophages abrogated proinflammatory cytokine expression ( Figure 6A ) but had minimal effect on p62 ( Figure 6H ).
In addition to binding to TLRs, palmitate is also internalized by macrophages ( Figure 6I ), and the kinetics of palmitate internalization and p62 accumulation in human macrophages was well correlated ( Figure 6I ). Furthermore, increasing the amount of palmitate ingested per cell by varying the ratio of palmitate to the number of MMe macrophages in culture markedly increased p62 accumulation ( Figure 6J ). Interestingly, ablation of Cd36 had no effect on palmitate uptake by BMDMs in vitro ( Figure S4) , and previous studies demonstrated normal palmitate uptake in Cd36 À/À ATMs (Nicholls et al., 2011) . Collectively, these findings suggest that CD36-independent palmitate uptake has a greater effect in suppressing autophagy and inducing p62 accumulation than palmitate recognition by cell surface TLRs.
DISCUSSION
ATM inflammation plays a key role in obesity-associated insulin resistance and type 2 diabetes (Chawla et al., 2011; Lumeng and Saltiel, 2011; Olefsky and Glass, 2010; Wellen and Hotamisligil, 2005) . A common observation reported in studying macrophages in obese mice and humans is that ATMs overexpress proinflammatory cytokines via signaling pathways that are operative in M1 macrophages, yet they cannot be identified when using cell surface markers of classical activation. One possible explanation for these discordant findings is that currently available surface markers for M1 macrophages, particularly in humans, may not be as specific as previously anticipated (Geissmann et al., 2010) . To circumvent this problem, we used a proteomics approach to define a set of cell surface proteins that (i) report classical activation in human monocytederived macrophages differentiated in the presence of M-CSF or GM-CSF (two well-established paradigms for generating macrophages in vivo), (ii) are maintained in macrophages exposed to mixed M1/M2 stimuli, (iii) are conserved between human and mouse macrophages, and (iv) are validated in vivo in a setting of chronic bacterial infection (CF patients).
Our findings show that markers identified by such stringent approaches still fail to characterize proinflammatory ATMs from obese subjects, both in omental and subcutaneous adipose depots. Similar findings were obtained in our analyses of ATMs isolated from obese mice in a DIO model. Collectively, these data provide strong evidence that proinflammatory ATMs do not adopt the classically activated M1 phenotype.
Our demonstration that cell surface markers of classical activation are primarily regulated by the type I interferon response may have important implications for how proinflammatory ATM phenotypes (and macrophage phenotypes in other diseases) are conceptualized in vivo. Thus, dissociation of mechanisms that control cell surface marker expression (how we detect macrophages) from pathways that control cytokine production (how we detect inflammation) enables these processes to be regulated independently. In a setting of classical activation, both pathways are coregulated by LPS (Beutler, 2004) .
However, our data show that metabolic stimuli promote inflammation without activating the type I interferon response, a finding that is consistent with the inability of M1 markers to identify MMe macrophages in vitro and proinflammatory ATMs in vivo. Moreover, this concept may not be restricted to settings of sterile inflammation, as bacterial products that are primarily recognized by TLR2 also produce inflammation without activating the type I interferon response (Toshchakov et al., 2002) , an observation that we confirmed experimentally. Based on these findings, it is likely that the repertoire of cell signaling pathways induced by a particular proinflammatory stimulus, and not necessarily the extent of inflammation, determines the cell surface markers that will ultimately be useful for interrogating that cell type in vivo.
Thus, we propose that cell surface markers of macrophages be used not to identify ''cellular phenotypes,'' but rather as robust indicators of specific cell signaling pathways that are activated in a given microenvironment. Our approach for using disease-specific conditions to define diagnostic surface markers and delineate mechanisms driving their expression can therefore provide insights into the signaling pathways engaged and the functional properties of the macrophages. In this respect, proteins regulated by the type I interferon response, which identify M1 macrophages, modulate host antiviral and antibacterial responses (Honda et al., 2005) . On the other hand, metabolic dysfunction and nutrient excess impose unique challenges for ATMs. Insulin resistance in the adipocyte leads to a continuous and excessive exposure of ATMs to FFA, particularly saturated FFA such as palmitate, which our data suggest plays a key role in triggering metabolic activation of macrophages. Thus, the induction of proteins involved in lipid metabolism, which delineate MMe macrophages, may enable these macrophages to appropriately buffer their environment from excessive lipids while maintaining cell health. Importantly, saturated FFAs upregulate proinflammatory cytokine expression in ATMs and fail to induce the M2 markers CD163, CD206, TFRC, and TGFBI (Becker et al., 2012; Martinez et al., 2006) , properties that clearly distinguish these cells from M2 macrophages, which also induce lipid metabolism through PPARg activation (Odegaard et al., 2007) .
On a molecular level, the metabolically activated macrophage phenotype is mediated by at least two independent mechanisms: a pathway involving palmitate binding to cell surface TLRs that drives proinflammatory cytokine production and a pathway mediated by palmitate internalization that activates p62 and PPARg, thereby promoting lipid metabolism and limiting inflammation ( Figure 7 ). The balance between these two processes determines the overall response of macrophages to metabolic dysfunction (i.e., pro-or anti-inflammatory) and can produce complex macrophage phenotypes spanning the spectrum between the ''M1-like'' and ''M2-like'' states. Indeed, our analyses demonstrate strong correlations between cell surface CD36 and ABCA1 levels on ATMs (markers often associated with M2 macrophages) (Martinez et al., 2006) and metabolic dysfunction in obese humans and mice. Concordant with our findings, previous studies suggested the presence of mixed macrophage phenotypes in obese human subjects and mice (Sica and Mantovani, 2012; Zeyda et al., 2007) .
Our model further predicts that excessive accumulation of palmitate within the macrophage would further attenuate or silence inflammation via p62 and PPARg activation and promote a more ''M2-like'' ATM phenotype characterized by increased lipid metabolism. Factors influencing the amount of FFAs ingested by macrophages include adipose tissue mass, adipocyte size, and extent of insulin resistance in the adipocyte, all of which would increase with the degree of metabolic dysfunction in patients with type 2 diabetes. In mice, we would expect that duration of high-fat feeding regimens and the mouse model of obesity used (Lep ob/ob develop more severe metabolic dysfunction than DIO) to greatly influence the ATM phenotype observed. Consistent with these assumptions, previous studies demonstrated that obesity-induced shifts in ATMs from a ''M2-like'' to a ''M1-like'' phenotype (Lumeng et al., 2007) are reversed when mice are fed a high-fat diet for extended periods of time (Shaul et al., 2010) . Similarly, recent work by Ferrante and colleagues showed that ATMs of obese Lep ob/ob mice (obese BW = 50-70 g) are not inflamed, but rather are characterized by increased lipid metabolism (Xu et al., 2013) . In our analyses of more mildly obese and insulin-resistant mice (DIO, obese BW = 30-35 g), we observed upregulated cytokine expression in ATMs. However, we also noted increases in genes involved in lipid metabolism, suggesting that the anti-inflammatory pathway is operative but not yet dominant. In summary, our findings demonstrate that metabolic dysfunction leads to a macrophage phenotype that is mechanistically distinct from classical activation, suggesting that disease-specific environments drive macrophage inflammation via different mechanisms. Importantly, our data do not imply that treating macrophages with adipose tissue or mixtures of glucose, insulin, and palmitate can holistically model the ATM phenotype, since conditioning environments in vivo are more complex and dynamic. However, our data suggest that metabolic activation is a suitable model for conceptualizing ATM phenotype and function, as it reconciles the seemingly contradictory findings of elevated proinflammatory cytokine expression in a cell expressing markers of an ''M2-like'' phenotype. Future gene knockout studies that specifically attenuate signaling pathways driving metabolic activation will be required to more carefully delineate its contribution to ATM inflammation and metabolic disease phenotypes in vivo.
EXPERIMENTAL PROCEDURES Ethics
All human studies were approved by the Institutional Review Boards at the University of Washington (IRB#13293), Seattle Children's Hospital (IRB#31279), and Fred Hutchinson Cancer Research Center (IRB#6874). Animal studies were approved by the Institutional Animal Care and Use Committee (ACUP#72209) at the University of Chicago.
Differentiation and Activation of Human Monocyte-Derived Macrophages
Peripheral blood monocytes were isolated from healthy donors and differentiated to macrophages in the presence of M-CSF (125 ng/mL) or GM-CSF (10 ng/mL), as previously described (Martinez et al., 2006) . Treatments and activations were performed for 24 hr as follows: M1, LPS (100 ng/mL) and IFNg (20 ng/mL); M2, IL4 (20 ng/mL); MMe, glucose (30 mM) and insulin (10 nM) and palmitate (0.4 mM); human adipose-tissue-conditioned media (1/10 dilution); Pam2CSK4 (100 ng/mL); and chloroquine (100 mM). Resultant macrophage populations were subjected to analysis by flow cytometry, qRT-PCR, immunoblotting, and PM proteomics.
PM Proteomics
Macrophage PM proteins were isolated using a membrane-impermeable biotinylation reagent (N-hydroxysulfosuccinimide-SS-biotin; Pierce), as previously described (Becker et al., 2012) . Mass spectrometric analyses and statistical analyses of proteomics data were performed essentially as previously described (Becker et al., 2010) . Full details are provided in the Supplement Information.
Bioinformatics Analysis
Functional analyses of the proteomics data were generated through the use of IPA (Ingenuity Systems; http://www.ingenuity.com). Informatics data were analyzed by the hypergeometric test with Benjamini-Hochberg correction.
Subject Recruitment (Elective Abdominal Surgeries) Human adipose tissue was obtained from anonymous donors undergoing abdominoplasty (n = 7) at Seattle Plastic Surgery or from study participants undergoing laparoscopic intra-abdominal surgeries (n = 7) at the Puget Sound Surgery Center in Edmonds, WA. Exclusion criteria included smoking; abuse of alcohol or other drugs; pregnancy; history of cardiovascular, autoimmune, or other chronic inflammatory disease; or current or recent use of antidiabetic, anti-inflammatory, or steroid hormone drug.
Adipose Tissue Collection and Processing
Human adipose tissue was collected by surgeons conducting abdominoplasty (subcutaneous only) or intra-abdominal surgery (subcutaneous and omental) and processed within 10 min by study staff. Stromavascular cells were isolated as previously described (Hagman et al., 2012) . In some instances, a 100 mg piece of freshly harvested adipose tissue was cultured in 1 mL media for 24 hr to obtain human adipose-tissue-conditioned media.
Subject Recruitment (CF) Spontaneously expectorated sputum was collected in clinic or sent overnight on ice from the patient's home. Study participants were older than 18 yr of age and had a confirmed diagnosis of CF. Exclusion criteria included significant hemoptysis within 2 weeks of collection or a prior lung transplant.
Sputum Processing
To solubilize sputum, samples were mixed with an equal volume of 0.1% DTT in PBS and placed on ice for 30 min with intermittent vortexing. Samples were passaged through sterile cotton gauze and filtered through 70-mm nylon gauze cell strainers. Cells were centrifuged at 300 3 g for 10 min at 4 C and washed four times with 50 ml RPMI to reduce debris. Cells were counted and assessed for viability using trypan blue exclusion. If contaminated with saliva, salivary components were aspirated from the sample prior to sputum processing.
Mouse Studies
Male C57BL/6 mice were obtained from Jackson laboratories. BMDMs were isolated as previously described (Becker et al., 2012) and activated along the MM1 and MMe pathways using identical conditions as for the human macrophages. For DIO studies, mice were fed a low-fat (Harlan Tekland; 2918) or high-fat (Research Diets Inc.; D12451) diets for 16 weeks. Epididymal adipose tissue was collected, washed, and subjected to collagenase digestion to isolate stromavascular cells, and ATMs were purified using anti-CD11b coupled magnetic beads (Miltyeni).
Flow Cytometry
Fluorochrome-labeled cells were analyzed according to the workflows presented in Figures S2 and S3. Analyses were conducted using a Canto-II or LSRII flow cytometer (BD Biosciences), and data were analyzed using FlowJo software v.9.4.11. Protein levels were quantified by mean fluorescence intensity and normalized to isotype to facilitate comparison between patients.
Antibodies
Antibodies for flow cytometric measurements of ABCA1, CD1c, CD11c, CD14, CD15, CD16, CD36, CD38, CD45, CD274, and CD319 were purchased from BD Biosciences (San Jose), Beckman Coulter (Danvers), Novus Biologicals (Littleton) BioLegend (San Diego), eBioscience (San Diego), or Miltyeni (Auburn).
ChIP
ChIP experiments were performed as previously described (Mutskov et al., 2002) using specific primers (Table S3 ) designed based on previously published PPARg ChIP-seq data (Mikkelsen et al., 2010) 
